BCM
LENZ

BML Capital Management’s LENZ Therapeutics LENZ Stock Holding History

BML Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,271
Closed -$268K – 28
2024
Q4 		$268K Sell
9,271
-50,729
-85% -$1.55M 0.17% 21
2024
Q3 		$1.42M Sell
60,000
-3,916
-6% -$86.9K 0.84% 17
2024
Q2 		$1.11M Hold
63,916
– – 0.79% 19
2024
Q1 		$1.43M Sell
63,916
-1
-0% -$21 0.94% 18
2023
Q4 		$1.17M Buy
+63,917
New +$1.06M 0.89% 22
2023
Q3 		– Sell
-21,756
Closed -$396K – 32
2023
Q2 		$396K Hold
21,756
– – 0.36% 25
2023
Q1 		$373K Buy
+21,756
New +$352K 0.32% 28

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BML Capital Management's LENZ Position: Q1 2025 in Review

BML Capital Management sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 9,271 shares — an estimated $268K sold.

BML Capital Management first reported a position in LENZ in Q1 2023 and held it in 7 quarters. The position peaked at $1.43M in Q1 2024. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

  • BML Capital Management reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BML Capital Management sold 9,271 LENZ Therapeutics shares in Q1 2025, an estimated $268K.
  • BML Capital Management first reported a position in LENZ Therapeutics in Q1 2023 and held it in 7 quarters.
  • BML Capital Management's LENZ Therapeutics position peaked at $1.43M in Q1 2024.
  • 105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on BML Capital Management's 13F filing for Q1 2025, filed 7 May 2025.